Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$27.50
-0.5%		$29.94
$27.23
▼
$38.44
$11.55B0.551.81 million shs1.14 million shs
Sanofi stock logo
SNY
Sanofi
$42.77
+0.1%		$43.95
$40.89
▼
$52.68
$103.69B0.352.02 million shs2.37 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.00%-4.89%-8.79%-9.91%-27.61%
Sanofi stock logo
SNY
Sanofi
0.00%-3.32%-2.31%-3.34%-9.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$27.50
-0.5%		$29.94
$27.23
▼
$38.44
$11.55B0.551.81 million shs1.14 million shs
Sanofi stock logo
SNY
Sanofi
$42.77
+0.1%		$43.95
$40.89
▼
$52.68
$103.69B0.352.02 million shs2.37 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.00%-4.89%-8.79%-9.91%-27.61%
Sanofi stock logo
SNY
Sanofi
0.00%-3.32%-2.31%-3.34%-9.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.00
Hold$31.9116.06% Upside
Sanofi stock logo
SNY
Sanofi
2.38
Hold$49.5015.74% Upside

Current Analyst Ratings Breakdown

Latest SNY and SNN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$33.88
9/10/2026
Sanofi stock logo
SNY
Sanofi
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/8/2026
Sanofi stock logo
SNY
Sanofi
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSector Perform
9/8/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
9/8/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
9/4/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
9/2/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight
8/31/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral
8/7/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/6/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
8/5/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$6.16B1.87$3.43 per share8.02$12.45 per share2.21
Sanofi stock logo
SNY
Sanofi
$49.35B2.10$7.07 per share6.05$33.27 per share1.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$625MN/AN/A11.901.49N/AN/AN/AN/A
Sanofi stock logo
SNY
Sanofi
$8.84B$1.9122.398.091.298.66%14.19%7.95%10/30/2026 (Estimated)

Latest SNY and SNN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
Sanofi stock logo
SNY
Sanofi
N/A$2.41N/A$0.17N/A$13.36 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.592.15%N/AN/AN/A
Sanofi stock logo
SNY
Sanofi
$1.764.12%+6.46%92.15%N/A

Latest SNY and SNN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.31202.05%10/2/202610/2/202611/6/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.62
2.14
1.11
Sanofi stock logo
SNY
Sanofi
0.21
0.99
0.64

Institutional Ownership

CompanyInstitutional Ownership
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%
Sanofi stock logo
SNY
Sanofi
14.03%

Insider Ownership

CompanyInsider Ownership
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
16,988419.93 million415.73 millionOptionable
Sanofi stock logo
SNY
Sanofi
74,8462.42 billion2.40 billionOptionable

Recent News About These Companies

Sanofi Partners With USA Pickleball On COVID-19 Protection Campaign
September 10 at 12:15 PM  |  rttnews.comhttps://www.rttnews.com/3690069/sanofi-partners-with-usa-pickleball-on-covid-19-protection-campaign.aspx
Archford Capital Strategies LLC Invests $1.42 Million in Sanofi $SNY
September 10 at 3:21 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-archford-capital-strategies-llc-invests-142-million-in-sanofi-sny-2026-09-10/
Astra, Roche win new outperform ratings as RBC initiates EU pharma coverage
September 9, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/astra-roche-win-new-outperform-ratings-as-rbc-initiates-eu-pharma-coverage/ar-AA2bTwWs
Sanofi (NASDAQ:SNY) Receives Average Recommendation of "Hold" from Brokerages
September 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997877
Sanofi (NASDAQ:SNY) Rating Increased to Buy at Wall Street Zen
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-sanofi-nasdaq-sny-rating-increased-to-buy-at-wall-street-zen-2026-08-29/
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
August 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2982003/sny-stock-trading-above-50-200-day-smas-buy-hold-or-sell?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2982003
Sanofi (NASDAQ:SNY) Receives Average Rating of "Hold" from Analysts
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-sanofi-nasdaq-sny-receives-average-rating-of-hold-from-analysts-2026-08-28/
US FDA approves updated COVID vaccines for 2026-27 season
August 27, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-updated-covid-vaccines-2026-27-season-2026-08-27/
Sanofi stock steadies after strong Q2 2026 and upgraded guidance
August 21, 2026  |  ad-hoc-news.deA
Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine
August 10, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/why-the-amlitelimab-setback-isnt-enough-to-sink-sanofis-multi-billion-dollar-engine-1804700/
Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine
August 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-amlitelimab-setback-isn-t-232940996.html
Sanofi 2026 Q2 - Results - Earnings Call Presentation
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933453-sanofi-2026-q2-results-earnings-call-presentation
Sanofi Says EU Expands MenQuadfi Approval
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sanofi-says-eu-expands-menquadfi-082017938.html
Sanofi’s MenQuadfi approved in EU for infants against meningococcal disease
August 5, 2026  |  msn.comhttps://www.msn.com/en-us/health/general/sanofi-s-menquadfi-approved-in-eu-for-infants-against-meningococcal-disease/ar-AA29mF40
Why Investors Should Look at L3Harris, Cenovus, and Sanofi
August 5, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23782/Why-Investors-Should-Look-at-L3Harris-Cenovus-and-Sanofi
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
August 4, 2026  |  manilatimes.netM
Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338016/0/en/press-release-sanofi-s-menquadfi-approved-in-the-eu-for-use-in-infants-from-age-six-weeks-against-invasive-meningococcal-disease.html
Sanofi SA (SNY) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance ...
August 1, 2026  |  sg.finance.yahoo.comhttps://sg.finance.yahoo.com/news/sanofi-sa-sny-q2-2026-190357494.html
Sanofi says weak decision-making hurt pipeline, promises more disciplined R&D
July 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/news/sanofi-says-weak-decision-making-hurt-pipeline-promises-more-disciplined-r-d/ar-AA295zOh
Press Release: Sanofi’s half-year financial report for 2026
July 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/press-release-sanofi-s-half-year-financial-report-for-2026-1036385587
Sanofi Q2 Business Earnings, Sales Rise; Raises 2026 Sales Guidance
July 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sanofi-q2-business-earnings-sales-090646150.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$27.50 -0.13 (-0.45%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$27.48 -0.01 (-0.04%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Sanofi stock logo

Sanofi NASDAQ:SNY

$42.77 +0.05 (+0.12%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$42.72 -0.05 (-0.13%)
As of 09/11/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas